This reports provides a data-driven overview of the current and future competitive landscape in GPP therapeutics.
More than 21,700 diagnosed prevalent cases of GPP are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for GPP.
The majority of marketed drugs indicated to treat GPP are monoclonal antibodies.
Out of eight molecules in the pipeline for GPP, the late-stage pipeline includes only one drug in pre-registration and one drug in Phase III.
Commercial sponsors lead the clinical trials space for GPP over the past 10 years. AbbVie is the top sponsor in GPP clinical research with seven clinical trials, of which two are in Phase III.
In deals involving companies developing GPP assets, acquisitions was the most prevalent deal type in North America and merger was the most prevalent deal type in Asia-pacific.
Scope
GlobalData’s GPP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the GPP market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GPP market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Findings
Disease Overview
Disease Etiology
Epidemiology Overview
Epidemiology Overview – Diagnosed Prevalent Cases of GPP in 2023 and 2028
Treatment Overview
Treatment Guidelines
Marketed Drugs Assessment
Marketed Drugs – Leading Marketed Drugs in GPP
Marketed Drugs – Overview by Mechanism of Action
Marketed Drugs – Overview by Route of Administration
Marketed Drugs – Overview by Molecule Type
Marketed Drug Profile – AbbVie's Skyrizi
Marketed Drug Profile – Novartis' Cosentyx
Marketed Drug Profile – UCB's Cimzia
Marketed Drug Profile – UCB's Bimzelx
Marketed Drug Profile – AstraZeneca's Lumicef
Marketed Drug Profile – Bristol-Myers Squibb's Sotyktu
Marketed Drug Profile – Boehringer Ingelheim's Spevigo
Pricing and Reimbursement Assessment
Marketed Drugs – Annual Cost of Therapy
Marketed Drugs – Time to Pricing and Reimbursement for Risankizumab
Marketed Drugs – Time to Pricing and Reimbursement for Secukinumab
Marketed Drugs – Time to Pricing and Reimbursement for Certolizumab Pegol
Marketed Drugs – Time to Pricing and Reimbursement for Bimekizumab
Marketed Drugs – Time to Pricing and Reimbursement for Brodalumab
Marketed Drugs – Time to Pricing and Reimbursement for Deucravacitinib
Marketed Drugs – Time to Pricing and Reimbursement for Spesolimab
Pipeline Drugs Assessment
Pipeline Drugs Overview – Late-Stage Pipeline Drugs in GPP
Pipeline Drugs – Overview by Development Stage
Pipeline Drugs – Overview by Mechanism of Action
Pipeline Drugs – PTSR and LoA in GPP
Pipeline Drugs – PTSR and LoA in Immunology and Psoriasis
Clinical Trials Assessment
Clinical Trials in GPP – Historical Overview
Clinical Trials in GPP – Overview by Phase
Clinical Trials in GPP – Overview by Status
Clinical Trials in GPP – Overview by Phase for Ongoing and Planned Trials
Clinical Trials in GPP – Trials with a Virtual Component
Clinical Trials in GPP – Geographic Overview
Clinical Trials in GPP – Single-Country and Multinational Trials by Region
Clinical Trials in GPP – Top Sponsors with Breakdown by Phase
Clinical Trials in GPP – Top Sponsors with Breakdown by Status
Clinical Trials in GPP – Overview by Endpoint Status
Clinical Trials in GPP – Overview by Race and Ethnicity
Clinical Trials in GPP – Enrollment Data
Clinical Trials in GPP – Overview of Sites by Geography
Clinical Trials in GPP – Top 20 Countries for Trial Sites